The country of origin of Gx Somatuline Depot (Lanreotide Acetate Injection)
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Ruling text
In your letter dated February 13, 2026, you requested a country of origin ruling on Gx Somatuline Depot on behalf of Pharmathen S.A. Gx Somatuline Depot, also identified as Lanreotide Acetate Injection, is an injectable medicinal preparation containing Lanreotide Acetate, a somatostatin analog, as the active ingredient. The product is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
It is also indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival and for the treatment of adults with carcinoid syndrome. In your letter, you stated that the active pharmaceutical ingredient (API) Lanreotide Acetate is sourced from China in lyophilized white powder form with a monomer peptide structure.
Your submission notes that non-China sources are also being assessed for future shipments. The Lanreotide Acetate API is imported into Greece, where it undergoes four main manufacturing steps to produce the final Lanreotide Acetate Injection in prefilled syringes. The manufacturing steps in Greece consists of the following: First, the Lanreotide Acetate powder is subjected to a vacuum and high-pressure compaction process.
This treatment increases the powder’s bulk density from less than approximately 0.06 g/mL to approximately 0.30 g/mL. The purpose of this operation is to improve the powder’s dosage uniformity, flowability, and compressibility for further processing and final product consistency. Second, the treated Lanreotide Acetate is hydrated using an aqueous acetic acid solution. The API is dissolved in the acetic acid solution to form a 24.6% w/w solution.
During this hydration step, the Lanreotide Acetate peptide chains begin to associate into dimer structures through non-covalent interactions, including hydrogen bonding and hydrophobic forces. Third, the hydrated material undergoes programmed homogenization cycles to form a semi-solid, high-viscosity gel. During homogenization, the dimer structures assemble into filament structures, which are long, linear assemblies of repeating dimer units.
The filaments then assemble into nanotube structures, which are hollow, cylindrical peptide assemblies. This processing converts the Lanreotide Acetate from a powdered monomer structure into a nanotube gel matrix. According to your submission, this structural transformation is essential to the product’s sustained-release, depot functionality because the gel matrix traps water and slows diffusion of the active substance over time. Finally, the semi-solid, high-viscosity gel is filled into plastic syringes.
The syringes are closed, assembled into the final device, labeled, placed in trays, packed in aluminum pouches and cartons, and palletized for gamma sterilization validation.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N358883).